English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the editor: In a recent issue of Eurosurveillance, Kelly et al. conclude that the risks associated with the 2010 trivalent influenza vaccine from CSL Biotherapies outweighed its benefits, based on a comparison of the risk of hospitalisation due to influenza compared with that arising from an adverse reaction [1]. However the analysis is misleading and the authors’ conclusions must be considered unsound.

Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children